Literature DB >> 21546603

Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation.

Chiadi E Ndumele1, Khurram Nasir, Raquel D Conceiçao, Jose A M Carvalho, Roger S Blumenthal, Raul D Santos.   

Abstract

OBJECTIVE: The goal of this study was to assess the independent and collective associations of hepatic steatosis, obesity, and the metabolic syndrome with elevated high-sensitivity C-reactive protein (hs-CRP) levels. METHODS AND
RESULTS: We evaluated 2388 individuals without clinical cardiovascular disease between December 2004 and December 2006. Hepatic steatosis was diagnosed by ultrasound, and the metabolic syndrome was defined using National Heart, Lung, and Blood Institute criteria. The cut point of ≥3 mg/L was used to define high hs-CRP. Multivariate logistic regression was used to assess the independent and collective associations of hepatic steatosis, obesity, and the metabolic syndrome with high hs-CRP. Steatosis was detected in 32% of participants, 23% met criteria for metabolic syndrome, and 17% were obese. After multivariate regression, hepatic steatosis (odds ratio [OR] 2.07; 95% CI 1.68 to 2.56), obesity (OR 3.00; 95% CI 2.39 to 3.80), and the metabolic syndrome (2.39; 95% CI 1.88 to 3.04) were all independently associated with high hs-CRP. Combinations of these factors were associated with an additive increase in the odds of high hs-CRP, with individuals with 1, 2, and 3 factors having ORs for high hs-CRP of 1.92 (1.49 to 2.48), 3.38 (2.50 to 4.57), and 4.53 (3.23 to 6.35), respectively.
CONCLUSIONS: Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased odds of high hs-CRP levels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21546603      PMCID: PMC3148106          DOI: 10.1161/ATVBAHA.111.228262

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  23 in total

1.  Test validity of periodic liver function tests in a population of Japanese male bank employees.

Authors:  E Yano; K Tagawa; K Yamaoka; M Mori
Journal:  J Clin Epidemiol       Date:  2001-09       Impact factor: 6.437

Review 2.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

3.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

4.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

5.  C-reactive protein and myocardial infarction.

Authors:  Pamela Sakkinen; Robert D Abbott; J David Curb; Beatriz L Rodriguez; Katsuhiko Yano; Russell P Tracy
Journal:  J Clin Epidemiol       Date:  2002-05       Impact factor: 6.437

6.  Human blood pressure determination by sphygmomanometry.

Authors:  D Perloff; C Grim; J Flack; E D Frohlich; M Hill; M McDonald; B Z Morgenstern
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

Review 7.  Novel clinical markers of vascular wall inflammation.

Authors:  G J Blake; P M Ridker
Journal:  Circ Res       Date:  2001-10-26       Impact factor: 17.367

Review 8.  Molecular mediators of hepatic steatosis and liver injury.

Authors:  Jeffrey D Browning; Jay D Horton
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics.

Authors:  Arnoldo Riquelme; Marco Arrese; Alejandro Soza; Arturo Morales; René Baudrand; Rosa María Pérez-Ayuso; Robinson González; Manuel Alvarez; Verónica Hernández; María José García-Zattera; Francisco Otarola; Brenda Medina; Attilio Rigotti; Juan Francisco Miquel; Guillermo Marshall; Flavio Nervi
Journal:  Liver Int       Date:  2008-07-16       Impact factor: 5.828

10.  The utility of radiological imaging in nonalcoholic fatty liver disease.

Authors:  Sherif Saadeh; Zobair M Younossi; Erick M Remer; Terry Gramlich; Janus P Ong; Maja Hurley; Kevin D Mullen; James N Cooper; Michael J Sheridan
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682

View more
  63 in total

1.  Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy.

Authors:  John R Koethe; Aihua Bian; Ayumi K Shintani; M Sean Boger; Valerie J Mitchell; Husamettin Erdem; Todd Hulgan
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-02       Impact factor: 2.205

2.  H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice.

Authors:  Vineesh V Raveendran; Karen M Kassel; Donald D Smith; James P Luyendyk; Kurt J Williams; Rachel Cherian; Gregory A Reed; Colleen A Flynn; Iván L Csanaky; Andrew L Lickteig; Matthew J Pratt-Hyatt; Curtis D Klaassen; Kottarappat N Dileepan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-22       Impact factor: 4.052

3.  The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Mahmoud Al Rifai; Michael G Silverman; Khurram Nasir; Matthew J Budoff; Ron Blankstein; Moyses Szklo; Ronit Katz; Roger S Blumenthal; Michael J Blaha
Journal:  Atherosclerosis       Date:  2015-02-07       Impact factor: 5.162

4.  Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study.

Authors:  Michelle T Long; Na Wang; Martin G Larson; Gary F Mitchell; Joseph Palmisano; Ramachandran S Vasan; Udo Hoffmann; Elizabeth K Speliotes; Joseph A Vita; Emelia J Benjamin; Caroline S Fox; Naomi M Hamburg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03-05       Impact factor: 8.311

5.  Association between clinical factors and self-underestimation of cardiovascular risk in subjects submitted to a routine health evaluation.

Authors:  Thais N Helou; Raul D Santos; Antonio G Laurinavicius; Marcio Sommer Bittencourt; Antonio E P Pesaro; Fabio G M Franco; Raquel D O Conceição; José A M Carvalho; Fernando M F Silva; Mauricio Wajngarten; Marcelo Katz
Journal:  Clin Cardiol       Date:  2018-01-22       Impact factor: 2.882

Review 6.  Metformin use among individuals at risk for type 2 diabetes.

Authors:  Lewis H Kuller
Journal:  Curr Diab Rep       Date:  2012-06       Impact factor: 4.810

Review 7.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 8.  Mechanisms of adverse cardiometabolic consequences of obesity.

Authors:  Carlos M Diaz-Melean; Virend K Somers; Juan Pablo Rodriguez-Escudero; Prachi Singh; Ondrej Sochor; Ernesto Manuel Llano; Francisco Lopez-Jimenez
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

9.  Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.

Authors:  Karen M Kassel; Bradley P Sullivan; Wei Cui; Bryan L Copple; James P Luyendyk
Journal:  Am J Pathol       Date:  2012-07-26       Impact factor: 4.307

10.  Associations between ambient air pollution and Hypertensive Disorders of Pregnancy.

Authors:  Zahra Mobasher; Muhammad T Salam; T Murphy Goodwin; Frederick Lurmann; Sue A Ingles; Melissa L Wilson
Journal:  Environ Res       Date:  2013-03-21       Impact factor: 6.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.